Literature DB >> 21983552

Combined application of autologous serum eye drops and silicone hydrogel lenses for the treatment of persistent epithelial defects.

Jin A Choi1, So-Hyang Chung.   

Abstract

PURPOSE: We investigated the utility of a combination of autologous serum eye drops and a silicone-hydrogel (SH) lens in the treatment of persistent epithelial defects (PEDs).
METHODS: Eight patients who had distinct PED conditions were treated with 50% (v/v) autologous serum eye drops in combination with silicone hydrogel contact lenses and prospectively observed.
RESULTS: The pathogenesis of PEDs included Sjogren-type dry eye syndrome, graft-versus-host disease, toxic keratitis, limbal cell deficiency, superior limbic keratoconjunctivitis, and neurotrophic keratitis. The patients had PEDs for 90±81.76 days (range: 30-240 days). Before the initiation of the combined treatment, three patients had already been unsuccessfully treated with SH lenses, and five patients had received serum eye drops alone. The PEDs of the eight eyes healed after a treatment period of 11.8±4.9 days. No visible deposits were noted on the surface of any contact lens.
CONCLUSIONS: These findings demonstrate that the combination of an SH lens and serum eye drops may be effective in the treatment of intractable PEDs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21983552     DOI: 10.1097/ICL.0b013e318233c9bb

Source DB:  PubMed          Journal:  Eye Contact Lens        ISSN: 1542-2321            Impact factor:   2.018


  13 in total

1.  Diffusion of Antimicrobials Across Silicone Hydrogel Contact Lenses.

Authors:  Alison M Zambelli; Kimberly M Brothers; Kristin M Hunt; Eric G Romanowski; Amy C Nau; Deepinder K Dhaliwal; Robert M Q Shanks
Journal:  Eye Contact Lens       Date:  2015-09       Impact factor: 2.018

2.  Bandage Contact Lenses versus Deproteinized Calf Blood Extract Eye Gel for Recurrent Corneal Erosion Syndrome: A Case-Control Study.

Authors:  Jing Li; Shaohua Tang; Yu Ma; Xiaohan Huang; Lanfang Xu
Journal:  Ther Clin Risk Manag       Date:  2020-11-13       Impact factor: 2.423

Review 3.  Corneal nerves in health and disease.

Authors:  Brittany Simmons Shaheen; May Bakir; Sandeep Jain
Journal:  Surv Ophthalmol       Date:  2014-01-23       Impact factor: 6.048

4.  Evaluation of the efficacy of 50% autologous serum eye drops in different ocular surface pathologies.

Authors:  Francesco Semeraro; Eliana Forbice; Osvaldo Braga; Alessandro Bova; Attilio Di Salvatore; Claudio Azzolini
Journal:  Biomed Res Int       Date:  2014-07-22       Impact factor: 3.411

5.  Undiluted Serum Eye Drops for the Treatment of Persistent Corneal Epitheilal Defects.

Authors:  Kaevalin Lekhanont; Passara Jongkhajornpong; Thunyarat Anothaisintawee; Varintorn Chuckpaiwong
Journal:  Sci Rep       Date:  2016-12-02       Impact factor: 4.379

Review 6.  Persistent Corneal Epithelial Defects: A Review Article.

Authors:  Uma Vaidyanathan; Grant C Hopping; Harry Y Liu; Anisha N Somani; Yasmyne C Ronquillo; Phillip C Hoopes; Majid Moshirfar
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2019

7.  Topical 100% serum eye drops for treating corneal epithelial defect after ocular surgery.

Authors:  Kaevalin Lekhanont; Passara Jongkhajornpong; Lulin Choubtum; Varintorn Chuckpaiwong
Journal:  Biomed Res Int       Date:  2013-07-30       Impact factor: 3.411

Review 8.  Towards the use of hydrogels in the treatment of limbal stem cell deficiency.

Authors:  Bernice Wright; Shengli Mi; Che J Connon
Journal:  Drug Discov Today       Date:  2012-07-27       Impact factor: 7.851

9.  The use of autologous serum for the treatment of ocular surface disease at a Swedish tertiary referral center.

Authors:  Joanna von Hofsten; Maria Egardt; Madeleine Zetterberg
Journal:  Int Med Case Rep J       Date:  2016-03-02

Review 10.  Bioengineering Approaches for Corneal Regenerative Medicine.

Authors:  S Sharareh Mahdavi; Mohammad J Abdekhodaie; Shohreh Mashayekhan; Alireza Baradaran-Rafii; Ali R Djalilian
Journal:  Tissue Eng Regen Med       Date:  2020-07-21       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.